Updates from guardian™ : a comprehensive registration programme
ARTIGO
Inglês
Agradecimentos: Medical writing support was provided by Andy Lockley of Bioscript Medical Ltd (Macclesfield, UK) and funded by Novo Nordisk Health Care AG (Zurich, Switzerland)
Turoctocog alfa is an approved B‐domain truncated recombinant factor VIII concentrate for adults and children with haemophilia A. Clinical data for turoctocog alfa have been reported from the guardian™1, guardian™2 and guardian™3 phase III trials. guardian™1 and guardian™3 phase III trials enrolled...
Turoctocog alfa is an approved B‐domain truncated recombinant factor VIII concentrate for adults and children with haemophilia A. Clinical data for turoctocog alfa have been reported from the guardian™1, guardian™2 and guardian™3 phase III trials. guardian™1 and guardian™3 phase III trials enrolled 150 adolescents/adults (≥12 yr), and 63 children (<12 yr), respectively, with previously treated severe haemophilia A and no history of inhibitors; 188 of these patients continued into the ongoing guardian™2 extension trial. In the three trials, patients have received prophylaxis with turoctocog alfa three times weekly or every second day, with breakthrough bleeds resolved to an expected postinjection level of ≥0.50 IU/mL. No safety concerns have arisen, and no patients have developed confirmed inhibitors (primary endpoint). Indeed, no confirmed inhibitors have been detected in >200 patients treated for a cumulative total of >54 000 exposure days in the phase III trials. Pooled efficacy data show a favourable long‐term effect of turoctocog alfa on annualised bleeding rate and a success rate for haemostatic response of 86%; 90% of bleeds were resolved with 1–2 doses. This article reviews the clinical development of turoctocog alfa with reference to the guardian™ clinical programme, describing results obtained to date and ongoing trials
Fechado
Updates from guardian™ : a comprehensive registration programme
Updates from guardian™ : a comprehensive registration programme
Fontes
European journal of haematology Vol. 95, no. S81, nespSpecial Issue: 12th Novo Nordisk Symposium on Haemostasis Management, Vienna, Austria, 4–6 June 2014 (Dec., 2015), p. 22, n. art. 29 |